Market Access

In the first part of his Pharma Commerce video interview, Philip Sclafani, PwC's pharmaceutical and life sciences lead, shares how he foresees the One Big Beautiful Bill Act reshaping prescription drug spending, and what strategies pharmaceutical companies adopt to mitigate its potential impact on innovation, R&D investment, and M&A activity.

The Spain-based CDMO strengthens its North American presence and capabilities through its purchase, while also acquiring a new rare disease treatment from Sanofi one month prior.

Is the industry ready for the Aug. 1 deadline of when these levies go into effect?

A JAMA Network Open study reveals that patients with private insurance can face monthly costs nearing $600 after a cancer diagnosis, highlighting the disparities based on cancer stage and calling for stronger financial support policies.

Kevin Chinn, vice president and head of the cell & gene therapy service line at Cencora, outlines why early planning, stakeholder engagement, and innovative access strategies are key to long-term CGT success.

In the fourth part of his Pharma Commerce video interview, Hyung Heon Kim, CEO of MetaVia, explains the market dynamics or stakeholder misalignments that need to be resolved in order for the next generation of weight-loss drugs to reach scale without overburdening payers.

In the third part of his Pharma Commerce video interview, Hyung Heon Kim, CEO of MetaVia, outlines alternative reimbursement or value-based contracting models that could be feasible in the short term, given CMS’ decision not to finalize coverage for obesity meds in 2026.

In the second part of his Pharma Commerce video interview, Hyung Heon Kim, CEO of MetaVia, explains how dual-action metabolic therapies can address clinical or tolerability gaps observed in first-generation GLP-1s.

In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Brad Stewart, BDO’s national life sciences co-leader, describes the immediate and long-term impacts of this potential levy on pharma imports.

In the first part of his Pharma Commerce video interview, Hyung Heon Kim, CEO of MetaVia, describes the US payer ecosystem’s level of preparedness to support broader access and long-term affordability for these therapies.

In the final part of his Pharma Commerce video interview, Murray Aitken, executive director, IQVIA Institute for Human Data Science, details how he sees the competitive landscape evolving

In the fourth part of his Pharma Commerce video interview, Murray Aitken, executive director, IQVIA Institute for Human Data Science, outlines what he anticipates for the biosimilar adoption curve in key markets moving forward.

In the third part of his Pharma Commerce video interview, Murray Aitken, executive director, IQVIA Institute for Human Data Science, explains the strategies that manufacturers should adopt to balance investment in innovation with lifecycle management.

In the second part of his Pharma Commerce video interview, Murray Aitken, executive director, IQVIA Institute for Human Data Science, suggests how pharma companies should revise their market access and pricing models to align with the evolving landscape.

The agreement grants LEO Pharma exclusive rights to the branded form of spesolimab for generalized pustular psoriasis and potentially, other IL-36–driven conditions.

In the first part of his Pharma Commerce video interview, Murray Aitken, executive director, IQVIA Institute for Human Data Science, describes the process behind developing the “Global Use of Medicines Outlook Through 2029” report.

Engaging the full workforce—from HR to R&D—can elevate launch outcomes, build trust, and create long-term brand ambassadors.

In the third part of his Pharma Commerce video interview, Marschall Runge, MD, PhD, dean of the University of Michigan Medical School and author of The Great Healthcare Disruption, proposes ways to ensure both fiscal responsibility and the sustainability of hospital funding.

The US president says the levies on pharmaceutical imports are imminent, but won’t take effect for a year to a year and a half.

Amid the push for reshoring and fiscal reform, the tariffs are part of a broader effort to rebalance trade and fund domestic initiatives, as the pharma sector awaits potential levies of its own.

A qualitative study explores how MA plan leaders, kidney care managers, and dialysis providers perceive the benefits, risks, and marketing practices surrounding MA enrollment for patients with end-stage kidney disease.

As drug development increasingly targets multiple indications, pharma companies must make strategic branding decisions—balancing regulatory requirements, market dynamics, and patient safety—to choose between single-brand or multi-brand approaches.

State Medicaid leaders create a plan to ensure safety, affordability, and equitable access for children and families living with rare diseases.

Analysis compares care quality and efficiency within physician groups that treat Medicare Advantage patients under at-risk contracts, versus fee-for-service.

When automatically moved from a zero-dollar silver plan to one that requires a premium due to plan turnover, do lower-income health insurance marketplace enrollees lose or switch coverage?